Ornn raised $33 million from a16z to build a GPU compute marketplace. The OCPI index is live on Bloomberg, and ICE plans to launch cash-settled compute futures based on it.
Space startups raised $43.5B in private funding in H1 2026 — a record pace driven by sovereign wealth funds, infrastructure PE, and defense VCs. Concurrently, the SpaceX IPO created a new public market benchmark. The orbital economy is becoming a permanent institutional allocation.
MindRank AI closed a $52M Series B to advance MDR-001, an AI-designed oral GLP-1 receptor agonist now in Phase III obesity trials in China. The round validates AI-native drug discovery at late-stage clinical development.
Helsing is betting $50 million on a West Virginia factory to produce 2,000 HX-2 AI-enabled strike drones per month before it holds a single US government contract.
AI-powered condensate-modulating therapeutics target previously undruggable proteins. Dewpoint's TDP-43 development candidate for ALS is the first real-world test of this new modality.
Ex-DeepMind founders who built poker-beating AI are now trading billions daily on the Nasdaq. Their Prague-based lab just raised a $500M+ Series A — Creandum's largest ever.
The space economy crossed $630 billion in 2026. This guide maps every major business opportunity — from billion-dollar government contracts to emerging startup niches.
Crystalys Therapeutics closed an oversubscribed $130M Series B to push dotinurad, a next-generation URAT1 inhibitor, through Phase 3 trials for gout. The drug is already approved in four Asian markets.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
